1. Introduction {#sec1-jcdd-02-00273}
===============

Takotsubo Cardiomyopathy (TC) was first described in 1991 in Japan. It consists of transient systolic dysfunction of the apical and/or mid-segment of the left ventricle, a clinical presentation of that mimics acute myocardial infarction and absence of obstructive coronary artery disease. Sparse data available on long-term outcomes suggests prognosis is not necessarily benign. We report the long-term follow-up of 12 TC patients, and speculate that intensive risk factor modification may account for the good outcomes we observed in this group.

2. Methods {#sec2-jcdd-02-00273}
==========

From January 1998 to December 2010, among 1651 who underwent emergent left heart catheterization for acute coronary syndrome (ACS), 12 patients were identified with having TC using the Modified Mayo Criteria. Main components include akinesia of mid-distal LV, non-obstructive Coronary Artery Disease (CAD), new EKG changes, and absence of myocarditis or pheochromocytoma ([Table 1](#jcdd-02-00273-t001){ref-type="table"}).

jcdd-02-00273-t001_Table 1

###### 

Demographic Characteristics.

  Patient Number   Follow up (Years)   Age (Year)   Sex      HTN   DM    CAD   Dyslipidemia   FH CAD
  ---------------- ------------------- ------------ -------- ----- ----- ----- -------------- --------
  A                13                  57           F        No    No    No    Yes            Yes
  B                17                  36           F        No    No    No    Yes            Yes
  C                9                   67           F        No    No    No    No             No
  D                8                   72           F        Yes   No    No    Yes            No
  E                7                   61           F        No    No    Yes   Yes            No
  F                10                  89           F        Yes   No    No    No             No
  G                6                   41           F        Yes   No    No    No             No
  H                6                   69           F        Yes   No    Yes   Yes            Yes
  I                5                   69           F        Yes   No    Yes   Yes            Yes
  J                5                   81           F        Yes   Yes   No    Yes            No
  K                5                   56           F        Yes   Yes   No    Yes            Yes
  L                8                   65           F        Yes   No    Yes   Yes            Yes
                                                    100% F   75%   17%   25%   67%            50%

All patients underwent follow-up evaluation of left ventricular function with transthoracic echocardiogram six weeks after the initial event, followed by yearly echocardiograms. We followed these 12 patients, who were actively managed with both lifestyle modification and pharmacologic treatment, over the 5--17 years period after the initial TC event.

Patients were advised regarding therapeutic lifestyle changes (TLC) and prescribed guideline-directed medical therapy (GDMT) for aggressive risk factor reduction. TLC included low-salt, low-fat diet, exercise, and cardiac rehabilitation. GDMT often included anti-platelet agents (aspirin, clopidogrel), beta-blockers (metoprolol or carvedilol), angiotensin converting enzyme inhibitors (ACEI) (lisinopril or ramipril), and statins (atorvastatin). The primary end point was a combination of all-cause death, cardiogenic shock, sudden cardiac death, recurrence of TC, and re-hospitalization for cardiac reasons.

3. Results {#sec3-jcdd-02-00273}
==========

All of the patients in our study were female and most were post-menopausal with a median age of 66 years (ranging from 36 to 89 years). Many had risk factors for coronary artery disease (CAD) with 75% (9/12) having hypertension, 67% (9/12) with hyperlipidemia, and 50% (6/12) with a family history of CAD. There were 25% (4/12) who already had a documented history of CAD. On presentation, 58% (7/12) had preceding emotional trauma and 50% (6/12) had physical stress ([Table 1](#jcdd-02-00273-t001){ref-type="table"} and [Table 2](#jcdd-02-00273-t002){ref-type="table"}). All patients presented with chest pain and troponin elevation, while 50% (6/12) had ST elevations on EKG. Coronary angiography revealed no obstructive lesion and left ventriculography revealed apical hypokinesis along with decreased ejection fraction (EF) in all patients ([Table 2](#jcdd-02-00273-t002){ref-type="table"}).

jcdd-02-00273-t002_Table 2

###### 

Clinical Features.

  Patient   Psychological Trauma   Physical Stress   Chest Pain   EKG                  Peak Troponin Elevation   Hypokinesis on Ventriculography
  --------- ---------------------- ----------------- ------------ -------------------- ------------------------- ---------------------------------
  A         Yes \*                 Yes ^\#^          Substernal   STE                  2.4                       Apical
  B         Yes \^                 No                Substernal   STD-inferior         42                        Inferior septal wall
  C         Yes                    No                Substernal   STE                  1.8                       Apical
  D         Yes                    No                Substernal   None                 1.4                       Infero-apical
  E         Yes                    Yes               Substernal   None                 10                        Apical
  F         No                     Yes               Left Sided   None                 1.85                      Apical
  G         No                     Yes               Substernal   STE-inferior         4.13; 1.79                Infero-apical
  H         No                     Yes               Substernal   STE-anterior         1.39                      Infero-apical
  I         No                     Yes               Left sided   LBBB                 1.37                      Apical
  J         Yes                    No                Substernal   STE-anterior         1.45                      Apical
  K         Yes                    No                Substernal   T-inv-inferior       3.34                      Infero-apical
  L         Yes                    No                Substernal   T-inv-inferior       1.5                       Infero-apical
                                                                  ST elevation = 50%                             

\* = Argument at work; \^ = Congenital problem in son; ^\#^ = yard work.

The patients in our study have been followed for 5 to 17 years, with an average follow-up of 8.3 ± 3.6 years. In all patients, echocardiograms performed four weeks after the initial event demonstrated recovery of EF along with normalization of cardiac contraction ([Table 3](#jcdd-02-00273-t003){ref-type="table"}). Further yearly follow-up echocardiograms showed that patients also maintained their ejection fraction for the duration of the study.

jcdd-02-00273-t003_Table 3

###### 

Management and follow up.

  Patient   Initial Ejection Fraction (Percentage)   Follow-up Ejection Fraction (Percentage)   Administered Medications                        Follow up (Years)   Chest Pain Recurrence   Documented CAD on Follow-up
  --------- ---------------------------------------- ------------------------------------------ ----------------------------------------------- ------------------- ----------------------- -----------------------------
  A         45                                       70                                         Aspirin, Metoprolol, Pravastatin Ramipril       13                  Yes                     No
  B         50                                       60                                         Metoprolol, Aspirin                             17                  No                      No
  C         25                                       40                                         Aspirin, Metoprolol, Clopidogrel, Ramipril      9                   No                      No
  D         35                                       55                                         Aspirin, Lisinopril, Metoprolol, Clopidogrel    8                   No                      No
  E         35                                       55                                         Metoprolol, Atorvastatin                        7                   No                      No
  F         35                                       61                                         Lisinopril, Carvedilol                          10                  Yes                     No
  G         50                                       55                                         Aspirin, Clopidogrel, Valsartan, Atorvastatin   6                   Yes                     No
  H         35                                       60                                         Aspirin, Clopidogrel, Metoprolol, Statin        6                   No                      No
  I         25                                       45                                         Aspirin, Lisinopril, Metoprolol, Statin,        5                   No                      No
  J         40                                       55                                         Aspirin, Statin, Lisinopril, Amlodipine         5                   No                      No
  K         30                                       50                                         Aspirin, Metoprolol, Statin, Lisinopril         5                   No                      No
  L         25                                       60                                         Aspirin, Statin, Carvedilol, Fosinopril \*\*    8                   Yes                     Yes

\*\* = Progression of CAD from 30% stenosis of RCA that was later found to be 90%.

There were four patients who experienced recurrences of chest pain. Two patients' symptoms were musculoskeletal in etiology. One patient had a progression of CAD, which was managed conservatively. One patient was found to have a malignant left lung mass. There was no cardiac mortality, and no recurrences of TC.

We followed the blood pressure, heart rate, body weight, and lipid panel results to ensure the patients are following optimal medical therapy and lifestyle modifications. The results are presented in [Table 4](#jcdd-02-00273-t004){ref-type="table"} and [Table 5](#jcdd-02-00273-t005){ref-type="table"}. During the follow up, one patient passed away with lung cancer. Her results will not be updated in the following tables.

After optimal, guideline-directed medical therapy (GDMT), almost all the patients had their blood pressure and heart rate controlled. The majority (8/11) of the patients had maintained or reduced body weight. The majority of the patients (9/11) had well-controlled LDL levels. The LDL level of patient A and patient D had worsened recently. Further review revealed that before these changes, their medical insurances were switched under the new healthcare law. Rosuvastatin was switched to generic Pravastatin and Atorvastatin. Follow up lipid panel results are pending.

jcdd-02-00273-t004_Table 4

###### 

Changes in blood pressure, heart rate, and body weight with medical management.

  Patient   Systolic Blood Pressure at Diagnosis   Most Recent Systolic Blood Pressure   Heart Rate at Diagnosis   Most Recent Heart Rate   Body Weight at Presentation   Most Recent Body Weight
  --------- -------------------------------------- ------------------------------------- ------------------------- ------------------------ ----------------------------- -------------------------
  A         122                                    132                                   62                        60                       144                           186
  B         132                                    120                                   83                        60                       142                           135
  C         124                                    120                                   72                        70                       156                           147
  D         193                                    120                                   74                        66                       99                            97
  E         130                                    128                                   68                        65                       172                           190
  F         156                                    104                                   74                        75                       130                           135
  G         140                                    111                                   72                        84                       115                           111
  H         116                                    106                                   117                       98                       182                           145
  I         167                                    141                                   85                        83                       266                           266
  J         131                                    128                                   62                        72                       149                           140
  K         135                                    128                                   102                       80                       356                           270
  L         117                                    125                                   90                        78                       164                           175

jcdd-02-00273-t005_Table 5

###### 

Lipid panel results after medical management.

  Patient   Initial Cholesterol   Most Recent Cholesterol   Initial LDL   Most Recent LDL   Initial HDL   Most Recent HDL   Initial Triglycerides   Most Recent Triglycerides
  --------- --------------------- ------------------------- ------------- ----------------- ------------- ----------------- ----------------------- ---------------------------
  A         169                   197                       71            112               59            53                124                     159
  B         164                   140                       80            60                65            66                91                      71
  C         159                   145                       90            73                61            58                76                      86
  D         164                   202                       87            127               60            59                85                      77
  E         212                   154                       135           95                52            56                168                     204
  F         153                   155                       101           93                37            46                72                      80
  G         168                   171                       73            79                82            79                61                      64
  H         172                   142                       113           63                19            26                202                     173
  I         168                   154                       99            81                32            36                187                     183
  J         151                   121                       73            59                30            19                238                     202
  K         154                   180                       66            74                36            58                258                     302
  L         119                   107                       54            37                50            35                75                      174

LDL = Low Density Lipoprotein; HDL = High Density Lipoprotein.

4. Discussion {#sec4-jcdd-02-00273}
=============

TC is increasingly recognized in the differential diagnosis of acute coronary syndrome (ACS) as a cause of myocardial infarction with normal coronary arteries (MINCA) \[[@B1-jcdd-02-00273]\]. Numerous studies document the short-term recovery of TC patients. A meta-analysis of 28 case series by Pilgrim *et al.*, showed complete recovery of EF in 95.9% of patients in 7--37 days, with ejection fraction improving from 20%--49.9% to 59%--76% \[[@B2-jcdd-02-00273]\]. Few studies, however, followed the long-term course of these patients.

The few studies following long-term outcomes in TC patients arrive at differing conclusions regarding prognosis. Elesber *et al.*, and Valbusa *et al.*, both tracked overall survival in age and gender-matched TC populations, but found no difference. In contrast, Sharkey *et al.*, and Ionesco *et al.*, found that survival in TC patients was reduced \[[@B3-jcdd-02-00273],[@B4-jcdd-02-00273],[@B5-jcdd-02-00273],[@B6-jcdd-02-00273]\]. Importantly, all of the aforementioned studies showed high cardiovascular event rates following the initial insult. In the follow-up by Elesber *et al.* during the 4.7 ± 4.8 years follow-up, 17% of patients suffered mortality, 10% of patients suffered recurrence of TC, and 12% of patients suffered re-hospitalization for cardiac reasons, for a total 39% event rate \[[@B5-jcdd-02-00273]\]. Ionesco *et al.* also saw this high event rate in their follow-up of 27 TC patients over a mean of 27 ± 16 months. 52% of patients reached a primary end point of a combination of all-cause death, cardiogenic shock, sudden cardiac death, and re-hospitalization for cardiac reasons, with the authors concluding that the long-term outcome of TC is worse than previously reported \[[@B3-jcdd-02-00273]\]. In a recent study, spectroscopy and imaging done four months after the initial TC event showed cardiac energetic impairment, adding more evidence of the long term impairment in health and well-being of TC patients \[[@B7-jcdd-02-00273]\].

In a recent prospective study by Looi *et al.*, 26% of patients had a complicated hospital course, 4% need circulatory support with an intra-aortic balloon pump, 6% need ventilatory support, 2% in-hospital mortality, and an additional 4% mortality soon after hospital discharge \[[@B8-jcdd-02-00273]\].

Meta-analysis by Singh *et al.*, 2014, showed that the in-hospital mortality rate of TC was 4.5%, but only 38% of the mortality was directly related to TC and complications. The remaining 62% of the mortality was due to underlying non-cardiac mortality. It brought the cardiac mortality from TC down to 1.5% \[[@B9-jcdd-02-00273]\].

In comparison, we found a trend towards a decrease in morbidity and mortality of TC patients who were prescribed cardiac medical therapy on discharge, indicating a possible benefit from a long-term management strategy ([Table 6](#jcdd-02-00273-t006){ref-type="table"}).

jcdd-02-00273-t006_Table 6

###### 

Comparing the Data from Previous Studies.

                                                Ionesco *et al.*   Elesber *et al.*   Khalighi *et al.*   Looi *et al.* 2012
  --------------------------------------------- ------------------ ------------------ ------------------- --------------------
  Number of Patients                            27                 100                12                  100
  Mean Age (years)                              68 ± 14            66 ± 13            64 ± 15             65 ± 11
  Follow/up Duration                            2.25 ±1.3 years    4.7 ±4.2 years     8.3 ± 3.6 years     3.0 ±1.7
  Patients Antiplatelet agent                   33%                50%                83%                 90
  Patients on BB                                33%                51%                83%                 65%
  Patients on ACE I/ARB                         41%                74%                83%                 63%
  Patients on Statin                            30%                32%                67%                 69%
  Overall patients on optimal medical therapy   34.3%              51.8%              79.0%               
  Results                                                                                                 
  Chest pain                                    2                  31                 4                   78%
  Hospitalization for cardiac complaints        8                  12                 1                   26%
  Recurrence of TC                              2                  10                 0                   7 (7%)
  Mortality                                     4                  17                 0                   4 (4%)
  Morbidity/Mortality                           14 (52%)           29 (29%) \*        1 (8%)              26 (26%)

Morbidity and mortality = hospitalization for cardiac reasons, death from any cause; \* event rate is 39% if we include recurrence of TC.

Medical therapy was targeted at preventing the mechanisms believed to cause TC: (1)Cardioselective beta blockers (carvedilol, metoprolol) to prevent myocardial stunning or microinfarction caused by catecholamine-induced sympathetic overdrive: Wittstein *et al.*, showed that catecholamine levels are 2--4 times higher in patients with stress-induced cardiomyopathy as compared to patients with myocardial infarction. \[[@B10-jcdd-02-00273]\] This is the most widely accepted mechanism leading to TC \[[@B10-jcdd-02-00273],[@B11-jcdd-02-00273]\].(2)Cardioselective beta-blockers, Calcium channel blockers and/or ACE-I/ARB may prevent coronary artery spasm---Lacy *et al.* \[[@B12-jcdd-02-00273]\] showed that stress from public speaking can lead to vasoconstriction of coronary artery segments. Kiuriso *et al*. demonstrated that three of 30 patients with TC had spontaneous multivessel epicardial coronary spasm on angiography, and 10 of 14 patients with TC had coronary spasms on a provocation test using either egonovine or acetylcholine.(3)Statins and anti-platelet agents to prevent microvascular dysfunction leading to transient thrombosis \[[@B2-jcdd-02-00273],[@B13-jcdd-02-00273]\]. In a study of 16 patients with TC, Bybee showed that all 16 patients had decreased coronary blood flow in at least one epicardial vessel and 10 patients had this in all three epicardial vessels \[[@B14-jcdd-02-00273]\]. In one of the earlier studies of TC, Sadamatsu *et al.* \[[@B13-jcdd-02-00273]\] studied the angiography of two patients with TC and found that both had reduced coronary flow reserve.

In cross-analysis with TC patients, followed long-term in other studies, we observed a negative correlation between the percentage of patients on cardiac medications and the subsequent adverse event rate. In contrast to previous studies, most patients in our study were placed on appropriate cardiac medications at the time of discharge ([Table 6](#jcdd-02-00273-t006){ref-type="table"}). They maintained their ejection fraction with only one patient requiring readmission for progression of CAD. Over a long period of follow-up, our patients did well with medical management, including TLC and GDMT. This suggests that aggressive risk factor reduction by medical management might explain the difference in long term prognosis of TC patients seen in these studies.

5. Limitations {#sec5-jcdd-02-00273}
==============

This is a single center trial with a limited number of patients without any control group. However, our study has the longest documented follow-up to prove the benefit of long-term medical management. However, due to limited power, we cannot specify which medication produced the greatest benefit.

Our results might also be compounded by selection bias since we followed 12 patients with Takotsubo Cardiomyopathy after discharge from hospital. We selected only the survivors. All of our patients survived the initial hospitalization. The biggest limiting factor to any conclusive statement regarding long-term prognosis and management is the relatively small number of patients available for such an analysis. As the diagnosis becomes more prevalent, future studies may be able to access a larger patient population for greater power.

6. Conclusions {#sec6-jcdd-02-00273}
==============

TC patients may be at risk of experiencing long-term cardiovascular events. Following 12 TC patients with TLC and GDMT, we observed recovery and maintenance of the ejection fraction, no cardiac mortality, and an excellent long-term prognosis. Risk factor reduction with TLC and GDMT may be effective in reducing the risk of long-term cardiovascular morbidity and mortality in TC patients.
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